

Fecal Microbiota Transplant Criteria Checklist

In order to undergo this treatment (fecal microbiota transplant), **all** inclusion criteria must be met.

Inclusion Criteria

- Age 18 years or older.
- Able to provide informed consent (patient or legal representative).
- Laboratory or pathology confirmed diagnosis of recurrent (within the previous 180 days) C. Difficile Infection (CDI) with symptoms as defined below.
- ≥ 2 episodes of CDI within 6 months.
- Adult patients suffering a third (or greater) documented episode of CDI.
- Adult patients who have failed to maintain CDI cure or who have not responded to standard therapy (which may include oral vancomycin or fidaxomicin).
- Previous treatment with at least one course of tapered/pulse dose vancomycin as per SHEA-IDSA C. difficile treatment guidelines; or, inability to taper or stop vancomycin without developing diarrhea requiring anti-infective therapy.

Symptoms of CDI include: diarrhea defined as: 3 or more unformed bowel movements in 24 hours for a minimum of 2 days with no other causes for diarrhea.

In order to undergo this treatment, (fecal microbiota transplant), **none** of the following criteria may be present or apply.

Exclusion criteria

- Patients under age 18.
- Patients who are pregnant.
- Patients who are nursing.
- Patients with neutropenia with absolute neutrophil count $<0.5 \times 10^9/L$.
- Active enteritis due to Salmonella, Shigella, E. coli 0157H7, Yersinia or Campylobacter.
- Severe underlying disease such that the patient is not expected to survive for at least 30 days.
- Patients with cognitive impairment or severe neuropsychiatric co-morbidities who are incapable of giving their own informed consent and who do not have an authorized legal representative.

Patients who are immunocompromised specifically:

- HIV infection (any CD4 count).
- Inherited/primary immune disorders.
- Immunodeficient or immunosuppressed due to medical condition/medication.
- Current or recent (<3 mos) treatment with anti-neoplastic agent.
- Current or recent (<3 mos) treatment with any immunosuppressant medications (including, but not limited to, monoclonal antibodies to B and T cells, anti-TNF agents, antimetabolites (azathioprine, 6-mercaptopurine), calcineurin inhibitors (tacrolimus, cyclosporine), mycophenolate mofetil).
- Patients with a history of severe (anaphylactic) food allergy.
- Patients who are American Society of Anesthesiologists (ASA) Physical Status classification IV and V.
- Patients with acute illness or fever on the day of planned FMT will be excluded with the option of being rescheduled.
- Any condition where, in the opinion of the physician, FMT treatment may pose a health risk to the patient.